P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001)

Bibliographic Details
Main Authors:	E. M. Stein, A. Patel, L. C. Michaelis, G. Schiller, R. Swords, L. A. Carvajal, G. Bray, J. DiMartino, M. Y. Levy
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000844984.10616.3d

Internet